AUSTRALIAN pharmaceutical firm Phebra has announced the establishment of a new wholly-owned subsidiary in the UK, with the aim of driving distribution of Phebra's exports of critical care injectables into the British market.
CEO Mal Eutick said Phebra UK would be based in London, with the company currently investigating which of the company's existing portfolio of drugs may be able to add value or serve unmet clinical needs in the UK.
"The UK market is not dissimilar to Australia and offers steady growth opportunities...we will be appointing experienced local staff to help facilitate the on-the-ground promotion and distribution for our products into this key market."
Eutick confirmed that Phebra had already submitted several new marketing applications to the UK Medicines and Healthcare products Regulatory Agency covering items used by haematologists, emergency care physicians and anaesthetists.
"We are anticipating that approvals to market these will be available by mid-2019," he said.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 18
